Retrospective analysis of nontraumatic subdural hematoma incidence and outcomes in Egyptian patients with end-stage renal disease on hemodialysis.

Ahmed Fayed, Ayman Tarek, Mohamed I Refaat, Sameh Abouzeid, Sohail Abdul Salim, Lajos Zsom, Tibor Fülöp, Karim M Soliman, Mohamed A Elmallawany

Journal: Renal failure 2022;43(1):1322-1328

PMID: 34547969

Abstract

BACKGROUND

The incidence of subdural hematoma (SDH) in chronic maintenance hemodialysis (CMH) patients may change over time, along with the evolving characteristics of the underlying populations.

METHODS

We conducted a retrospective, single-center study at Cairo University hospitals, assessing the incidence, associated risk factors, and outcomes of nontraumatic SDH in CMH patients between January 2006 and January 2019.

RESULTS

Out of 1217 CMH patients, nontraumatic SDH was diagnosed in 41 (3.37%) during the study, increasing with the enrollees' age but stable over the observation period and translating into an annual incidence rate of 28 per 1000 patients per year. SDH patients were likely to use central venous catheters, reported pruritis and history of bone fractures, and had higher phosphorus, parathyroid hormone, and alkaline phosphatase values ( < 0.001); however, there was no association with atrial fibrillation or use of anticoagulants. In the SDH cohort ( = 41), six patients did not need surgical intervention and 13 patients died before becoming surgically fit for intervention; mortality correlated with ischemic heart disease ( = 0.033) and the presence of atrial fibrillation or chronic anticoagulation with warfarin ( < 0.0001 for both), among others. Twenty-two patients received surgical operations and of these 2 died postoperatively; overall patient mortality was 12/41 (29.27%) at 30 days and 15/41 (36.59%) at 1 year.

CONCLUSION

Our study demonstrated a striking enrichment for underlying comorbidities in those patients developing SDH and a high risk of immediate mortality. The benefit of chronic anticoagulation therapy should be carefully weighed against the risk of CNS bleed in MHD patients.

Address: Nephrology Unit, Internal Medicine Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.; Neurosurgery Department, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt.; Nephrology Department, Theodor Bilharz Research Institute, Cairo, Egypt.; Department of Medicine, Division of Nephrology, University of Mississippi Medical Center, Jackson, MS, USA.; Fresenius Medical Care Hungary, Cegléd, Hungary.; Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.; Medical Services, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.; Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.; Department of Surgery, Transplant Nephrology, Medical University of South Carolina, Charleston, SC, USA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.